Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Sterling Biotech Ltd

    Sterling Biotech Limited (SBL), promoted by Mr. Nitin Sandesara (Managing Director), is the flagship and a listed company of the Vadodara based Sandesara group. SBL is mainly en

  • No Image
    Strides Arcolab Ltd

    Headquartered in India, Strides Arcolab is a pharmaceutical company with a key focus on development and manufacture of IP-led niche generics and bio-pharmaceuticals. It is also

  • No Image
    Sulfozyme Agro India Pvt ltd

    Sulfozyme Agro India Pvt.Ltd specializes in manufacturing and supplying zinc sulphate. Their products include zinc sulphate heptahydrate, zinc sulphate monohydrate, manganese su

  • No Image
    Sun Pharmaceutical Industries Ltd

    Sun Pharmaceutical Industries Ltd is a leading Indian pharmaceutical company engaged in developing, manufacturing and marketing of formulations and A